$KTOV so LLY just announced their definitive agreement to acquire Disarm Thera. for 135mill upfront and up to 1.225 billion in future milestones etc. Sure, we would all rather see KTOV being the one acquired, but that doesn't mean they won't; Lilly has plenty of money leftover to seek another acquisition. Silver lining - Alzheimer's was one of NT219s targets? Disarm Thera. focuses on axonal degeneration which can be triggered by, among other diseases, Alzheimer’s. If I were Isaac, and talks were ongoing, I'd be selling the shit outta my product 😂🤷‍♂️
2 Likes